Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer

David N. Brown, Irene Caffa, Gabriella Cirmena, Daniela Piras, Anna Garuti, Maurizio Gallo, Saverio Alberti, Alessio Nencioni, Alberto Ballestrero, Gabriele Zoppoli

Research output: Contribution to journalArticlepeer-review


SQLE encodes squalene epoxidase, a key enzyme in cholesterol synthesis. SQLE has sporadically been reported among copy-number driven transcripts in multi-omics cancer projects. Yet, its functional relevance has never been subjected to systematic analyses. Here, we assessed the correlation of SQLE copy number (CN) and gene expression (GE) across multiple cancer types, focusing on the clinico-pathological associations in breast cancer (BC). We then investigated whether any biological effect of SQLE inhibition could be observed in BC cell line models. Breast, ovarian, and colorectal cancers showed the highest CN driven GE among 8,783 cases from 22 cancer types, with BC presenting the strongest one. SQLE overexpression was more prevalent in aggressive BC, and was an independent prognostic factor of unfavorable outcome. Through SQLE pharmacological inhibition and silencing in a panel of BC cell lines portraying the diversity of SQLE CN and GE, we demonstrated that SQLE inhibition resulted in a copy-dosage correlated decrease in cell viability, and in a noticeable increase in replication time, only in lines with detectable SQLE transcript. Altogether, our results pinpoint SQLE as a bona fide metabolic oncogene by amplification, and as a therapeutic target in BC. These findings could have implications in other cancer types.

Original languageEnglish
Article number19435
JournalScientific Reports
Publication statusPublished - Jan 18 2016

ASJC Scopus subject areas

  • General


Dive into the research topics of 'Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer'. Together they form a unique fingerprint.

Cite this